Answers are grounded in this paper and cite their sources.
Assessment of the clinical benefit of [18F]-FDG PET/CT examinations in restaging of patients with non Hodgkin lymphoma (NHL) in Egypt. This study was performed on 45 patients with NHL. PET-CT and CECT were analyzed after end of chemotherapy regimen, using 12 months follow-up as standard of reference. Follow-up of patients with NHL after 12 months of treatment revealed significant differences between staging by CT versus PET/CT (P = 0.0001). Disease was upstaged by PET/CT in 36% (mostly in stages I and II) and downstaged in only 2% of patients. Agreement between PET-CT & CECT were usually in stage III and IV. Evaluation showed a sensitivity of 77% for CT alone, 95% for FDG-PET-CT. FDG PET-CT significantly improved sensitivity and specificity in restaging of NHL and therefore should be used routinely in follow up of patients with lymphoma.
No takes yet. Share an insight, caveat, or question.
Elshafey et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: